menu
    • menu
    [{"orgOrder":0,"company":"Pharmacare Premium","sponsor":"Midas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MALTA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pazopanib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacare Premium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmacare Premium \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacare Premium \/ Midas Pharma"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pazopanib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Auro Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pazopanib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Auro Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Auro Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Auro Pharma Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pazopanib

    Menu

    Pazopanib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Eugia Pharma

    India arrow
    Bio-Europe Spring
    Not Confirmed

    Eugia Pharma

    India arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Eugia Pharma Receives USFDA Approval for Pazopanib Tablets, 200 mg

    Details : Votrient-Generic (pazopanib HCl) is a multi-kinase inhibitor, which is indicated for the treatment of adults with advanced renal cell carcinoma & advanced soft tissue sarcoma.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 05, 2024

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Auro Pharma Inc

    Canada arrow
    Bio-Europe Spring
    Not Confirmed

    Auro Pharma Inc

    Canada arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Auro Pharma Arm Gets USFDA Nod for Pazopanib Tablet

    Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 05, 2024

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Pharmacare Premium

    Malta arrow
    Bio-Europe Spring
    Not Confirmed

    Pharmacare Premium

    Malta arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Study Phase : Phase III

    Sponsor : Midas Pharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Midas Pharma’s Partner, the Malta-based Generics Developer Pharmacare Premium, Has Successfully Conducted BE...

    Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.

    Product Name : Vorient-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 26, 2021

    Lead Product(s) : Pazopanib Hydrochloride

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Sponsor : Midas Pharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth